IL13RA2 and glioblastoma: Tandem CAR T-cells targeting EGFRVIII and IL-13R α2 appear to be a potentially attractive approach based off preclinical data using patient-derived xenograft mouse models, which demonstrated long term durable and complete responses against heterogeneous GBM tumors (48).